Latest / "Isn't That Interesting?!": Breast Cancer Survivor Stories + Remarkable Research / Season 4 / Episode 8: Dr. Karen Anderson
Transcript
- 0:00We're born with a built in safety net.
- 0:02Our immune system is always on alert, working to defend us from
- 0:06invaders, even cancer. A Mayo Clinic oncologist is
- 0:10looking at how we might use that natural defense system to detect
- 0:13breast cancer earlier using something called adaptive
- 0:17immunityearlier.org helped with a pilot study, and now Martha
- 0:21Kaylee gets the inside scoop in this week's episode of Isn't
- 0:25That Interesting? Thank you all for joining us.
- 0:28And this is Doctor Karen Anderson.
- 0:31And she has her clinic at Mayo Clinic, but she also has an
- 0:35appointment at Arizona State, is that right?
- 0:38And the conferences center there.
- 0:41So she has got she has been an interesting approach and I think
- 0:47that it is so exciting and I can't believe that she's been
- 0:52working on this for so long because it just seems like it is
- 0:56exploding and findings. And so I'm going to let her talk
- 1:00to you about the auto antibodies, which I just I'm so
- 1:05amazed at your work to be able to look at it from not just one
- 1:11approach, but from different approaches.
- 1:14So I'm going to, I'll probably ask you some dumb questions, but
- 1:16that's OK. I think my honest is getting
- 1:19used to that sometimes. So, so go ahead and just welcome
- 1:23to our to the podcast. Well, first.
- 1:26Of all, I just want to say thank you and thank you for having me.
- 1:29And you're actually, I'm going back a little bit to my roots.
- 1:32I'm I did my MDPHD at Duke. I needed that.
- 1:36I didn't want. To yeah, so you know, North
- 1:38Carolina is is is a fair bit of family in parts of North
- 1:43Carolina over the years. And so this is wonderful to come
- 1:46back to this and, and this is a topic that is, you know, very
- 1:52near and dear to my heart about how, how can we really diagnose
- 1:55breast cancer earlier? How can we, you know, shift the
- 1:59needle, catch it earlier, minimize the toxicities from
- 2:02treatments by having an earlier stage breast cancers.
- 2:05And especially in, in our modern era where we're seeing more
- 2:10younger women with breast cancer, How can we really, you
- 2:13know, improve our detections? And, and, and part of the, by
- 2:20doing some of this biology about what's happening early on in,
- 2:23in, in breast cancer development, you can start to
- 2:27develop therapies. We, we call them interception.
- 2:30You know, can we intercept the cancer in that time frame from
- 2:33when those cells start to go wrong to when they actually turn
- 2:37into, you know, either pre invasive or invasive breast
- 2:40cancers? And the more we understand about
- 2:43that window of time, the more you can start to think about
- 2:46intervening interception, prevention type of A approaches.
- 2:50So I come at this. So two things.
- 2:52One is I am a breast cancer medical oncologist.
- 2:55I do see patients at Mayo Clinic in Arizona.
- 2:58When I first got to know you and your organization, I was in
- 3:01Boston at Dana Farber and, and I've been practicing in, in as a
- 3:06breast cancer medical oncologist for more years than I care to
- 3:10admit. So, but, but even before then, I
- 3:14studied immunology and I have, I did an MDPHD at Duke and I
- 3:20studied immunology and what we call adaptive immunity.
- 3:23So this is the not just antibodies, but also T cells.
- 3:28Adaptive immunity is the ability of your immune system to, to
- 3:34adapt to new things that that come at us.
- 3:36So think about it. You know, the immune system has
- 3:38this incredible Sentinel, right? It you, it has to be able to
- 3:44react to things it hasn't seen before.
- 3:47It has to have all that molecular variation to be able
- 3:50to say, oh, this is a virus, this is a new virus.
- 3:54I'm going to see if I can attack this virus and I'm and I'm going
- 3:58to have memory, immunologic memory, so that the next time I
- 4:01see it, I'm going to be prepared.
- 4:04And, and I find that fascinating molecularly.
- 4:07And, and you know how that works structurally, you know, this is
- 4:11billions and billions of different types of receptors
- 4:14that we have, these antibodies that we create and these T cells
- 4:17that we create. And so a couple decades ago, I
- 4:21started studying that that molecular basis of of
- 4:25autoimmunity, not, not, not of autoimmunity, but but of this
- 4:28adaptive immunity. And we were looking at it for
- 4:33vaccine development. We were looking at it for
- 4:37infectious diseases. And then I started looking at it
- 4:40for cancer. You know, are we seeing these
- 4:43changes that happen in cells early?
- 4:47Is your immune system already seeing some of this?
- 4:50And could we exploit that to try to find early detections for
- 4:54cancer? And it it's a very fair
- 4:57question. There have been, there have been
- 4:58studies looking at auto antibodies.
- 5:00That's 1/2 of that adaptive immunity immune system and the T
- 5:06cells are kind of the other half.
- 5:07But we were looking at at auto antibodies in part because it's
- 5:10a little bit easier to do. But the challenge of of does to
- 5:15do tumors, you know, cancer happens because of mutations,
- 5:19cancer happens because of changes in these cells, right.
- 5:22And the immune system sees changes in things.
- 5:27And so it turns out your immune system is continually monitoring
- 5:32yourself and monitoring these emerging mutations and these
- 5:37emerging changes and changes in protein structure and changes in
- 5:41glycosylation patterns and, and invasion and everything.
- 5:44And so, so there is this that's happening sort of behind us.
- 5:48In fact, your immune system is actually editing those cancers,
- 5:51we call it. It's actually giving immunologic
- 5:54pressure and changing the way they grow and develop and
- 5:58probably eliminating a lot of them before we ever see it,
- 6:02which I find fascinating. The fact that you can, you know,
- 6:05cancer is patrolling and doing the surveillance and this
- 6:07editing and this changing over time.
- 6:10And obviously if we get cancer, then the immune system has fatal
- 6:13at doing that. And but how early is early can
- 6:17we exploit this for for early detection?
- 6:20So, so that's how I got kind of got started on it.
- 6:23And I can get into some of the technical things about how we do
- 6:27it, but but it and and sort of where it's going at as this
- 6:33emerges down the line. But but that's how it all kind
- 6:36of got started. Right.
- 6:38And So what I find so interesting is that it's
- 6:43described as to be able to monitor these for ductal
- 6:47carcinoma and psyche, which I think is very critical.
- 6:51And, and the concern that by that I have is like for so many
- 6:57women, they are told that they have breast density.
- 7:02Well, you know, and so that's like, well, OK, what do I do
- 7:06with that? You know, do I, do I worry, do
- 7:09I, I mean, how, how do I monitor that?
- 7:12And so it leaves you like, what, what, what does that?
- 7:16What does purpose does that serve for me?
- 7:19So. So could it help with wherever
- 7:23you are by discerning these changes in the immune system?
- 7:28Could it even be before there's ductal carcinoma and psychic?
- 7:32So it's interesting when we look back there's there's no question
- 7:36that some women are can develop auto antibodies and that can be
- 7:41detected maybe six months or a year ahead of time.
- 7:45Is that is that long enough to be clinically important?
- 7:48Probably. But this is true not just for
- 7:52breast cancers, it's also true for ovarian cancer.
- 7:55It's also true on subsets of, you know, lung cancers and
- 7:59pancreatic cancers in others, right?
- 8:01Breast cancer is a little bit harder because it's, they're
- 8:05oftentimes these are small tumors so that are embedded in
- 8:08fat. So they're not really that
- 8:11accessible into the bloodstream. They're not shedding a lot of
- 8:14molecules into the bloodstream that then we can go find and and
- 8:17I think that's been true. That's been true for nucleic
- 8:20acid testing and it's been true for methylation testing and
- 8:24other kinds of things that you can find the bloodstream.
- 8:27We look at proteins, but but I think that's been one of the
- 8:30challenges to develop molecular tests for early breast cancer
- 8:35and DCIS or ductal carcinoma in site you is that pre invasive
- 8:39type of breast cancer that's particularly hard to find
- 8:42because it's still very, very much contained within the ducts
- 8:46within the breast. And so you're not it's not
- 8:48really getting in there that much.
- 8:51But this is something where I think immunologic approaches
- 8:56because the immune system essentially sees these changes
- 8:59fairly sensitively and then amplifies it because the you
- 9:03know, it's saying, oh, there's something different there.
- 9:05We have to make more antibodies, for example, to it.
- 9:08So it kind of like self amplifies the signal.
- 9:12But the problem isn't, and what we've found is that there's only
- 9:15a subset of women that are seeing who are mounting these
- 9:18antibody responses. A lot of people are not.
- 9:21So the sensitivity of these, some of these molecular tests,
- 9:24they're a little bit low. They can be quite specific.
- 9:28And there's certain molecular changes that happen in breast
- 9:31cancer that are very immunogenic.
- 9:33So mutations in P53 is something that's very immunogenic that
- 9:36happens a lot in triple negative breast cancers and and there are
- 9:42other, you know, sort of mutations and changes that that
- 9:45that these antibodies can see, but it hasn't it, they're
- 9:49specific but not quite sensitive enough.
- 9:51So what we did was we combined some of those auto antibody
- 9:56tests with some of the protein tests that were more sensitive
- 9:59and not as specific. And so if you combine that you
- 10:01can kind of come up with a little bit more combined test.
- 10:05Some of those were were tested in in clinical use.
- 10:09They were licensed out to a company called Provista a number
- 10:12of years ago and and ultimately ended up being a a non FDA
- 10:16approved test called the Dessa breast that was used had had
- 10:20been used clinically to some level, but but ultimately needed
- 10:24really more validation for for FDA clearance.
- 10:29And but, but it was clear that the, you know, in in big blinded
- 10:33studies that we could distinguish between
- 10:36indeterminate mammograms and and try to help guide this.
- 10:40But I want to get back to your, your, your point about breast
- 10:44density. And I think this is, this is
- 10:46really important point, right? We know that women are at
- 10:50elevated risk and women with elevated breast density, it's
- 10:53like a double whammy we have. You're at increased risk,
- 10:57significantly increased risk of getting breast cancer and at the
- 11:01same time we can't see it as well.
- 11:03You're. Not as effective with this.
- 11:07And so a lot of the efforts have been do we do we improve the
- 11:12imaging rules? Can we think about, are there
- 11:16therapies that might be able to reduce breast density without
- 11:19causing a lot of side effects? I, I, I think it's a big
- 11:21unknown. And the other part of this is
- 11:24what the heck is causing that? Is that genetics?
- 11:27Is that the Exposo zone? You know what we eat, what we
- 11:31drink and what we're exposed to? You know what we're bathing in?
- 11:34I don't know right. All of that exposures that we're
- 11:37seeing. So we have the breast density
- 11:39challenge and then we also have the this increasing rates of
- 11:42younger women with breast cancer when the mammograms are not as
- 11:45effective. And then under 40, those
- 11:48mammograms are not as effective. And we are seeing an increased
- 11:52rates of those breast cancers. And and we really need other
- 11:57ways of testing in particular for the ones that stay hidden on
- 12:02mammograms. And there are better imaging
- 12:06tools, certainly contrast mammograms and Mris and targeted
- 12:11ultrasounds. But I think there, there's
- 12:14opportunity where part of that imaging field is going is, is
- 12:19developing imaging markers specifically for the breast
- 12:24cancer. So it's not just simple X-rays,
- 12:27but, but doing target sort of targeted imaging.
- 12:29And I think that that we'll see that over the next 1020 years.
- 12:34It's going to take a little while to kind of get out there.
- 12:36But, but, but I also think that these kinds of blood tests,
- 12:40that's a role for where blood tests and, and the changes that
- 12:45might be happening systemically as a reaction to it, that might
- 12:49also be an important tool when the imaging is a little bit less
- 12:54effective. Does that make sense?
- 12:55Yeah. And it makes a lot of sense.
- 12:58And I think that it was for me, the thinking is that AI is going
- 13:03to help with the imaging ability to sensitize it a bit stronger.
- 13:09But I just do work. I think about the changes we
- 13:13interviewed, Jennifer Put. From Oh good.
- 13:16Yeah, she was great. And she, she talked about, you
- 13:20know, the evolution of the cancer cell and it was like, it
- 13:23starts as a cell and then it goes to atypical.
- 13:25And I said, so, So what takes it to atypical?
- 13:30And she said, well, we don't know that and I don't figure
- 13:33that out. How we get to the atypical and
- 13:36then what do we do? So do you have any thoughts on
- 13:39that? Yeah.
- 13:40Well, my simple answer is no, right?
- 13:42It it, it's an accumulation of mutations, right.
- 13:45And, and breast cancer, like most solid tumors, it's not one
- 13:48thing, it's not some catastrophic genetic change in
- 13:52the cell. It's an accumulation of
- 13:55alterations. And that that can be mutations,
- 13:58that can be breaks in the chromosome, that can be
- 14:00epigenetic changes with just these marks that, that, that,
- 14:05that really methylation marks that on the DNA itself.
- 14:10That changes what gets expressed where on Hannibal, but it's
- 14:13also, it's also changes in self and, and remember, so adaptive
- 14:20immunity, I'm, I'm always going to come back to adaptive
- 14:22immunity. So I remember walking into my
- 14:27ultimately my PhD advisor's office.
- 14:30I didn't know that at the time. I was talking to people about
- 14:32what lab I wanted to go in at Duke.
- 14:34And, and he had this clipped British accent and his name was
- 14:39Peter Creswell. And, and he said, well, we
- 14:41studied the difference between self and non self and how the
- 14:44immune system distinguishes that.
- 14:46And I said, well, that makes perfect sense.
- 14:48And then he proceeded to talk for 15 minutes.
- 14:49I had no idea what he was talking about.
- 14:52I couldn't understand the thing. And it wasn't until I, I, I, I
- 14:55took immunology that I kind of understood these molecules that
- 14:58he was studying. And it took me a while to
- 14:59realize he was getting at the heart of how the adaptive immune
- 15:04system works. And, and I was like that, that,
- 15:07that sounds great. It, it does try to distinguish
- 15:10what's foreign from what's not or in the setting of cancer and,
- 15:14and cancer evolution, right? The evolution of these cells
- 15:18that are different, what's different in that cell versus
- 15:21not. And we know that, that as that
- 15:25cell can change, those T cells can target this and can remove
- 15:29them and get rid of them before we ever see them in that
- 15:33process. But you've got these mutations
- 15:35that are happening, these changes in chromosomes, these
- 15:37changes in methylation marks that sort of are evolving.
- 15:41And then meanwhile, the cell is growing maybe just a tiny little
- 15:45bit faster, and maybe it can steal the food a little bit
- 15:48better from the cells around it, right?
- 15:50The oxygen and the glucose and all the things that it needs to
- 15:53grow and develop and it's probably accumulation of four or
- 15:57five different changes within there that ultimately turn it
- 16:01into what we call the hallmarks of cancer.
- 16:04You know, being able to grow and being able to replicate and
- 16:07stabilize its genome and invade and migrate and all these things
- 16:11that that that make a cancer what it is.
- 16:15The immune system though, as it's seeing this the way the,
- 16:20the adaptive immunity when, when we started working on this, the
- 16:24idea about cancer immunology and immunotherapy was still very
- 16:29kind of on the fringe. The, the preclinical models were
- 16:35suggesting that, that we could target the immune system, boost
- 16:39it up, make it a little bit more effective and, and be able to
- 16:42treat some cancers. But the therapies for it had
- 16:47failed and failed and failed again.
- 16:50And, and in fact, I was advised to get out of the field.
- 16:54I'll be honest with you. They're like just get into
- 16:56genetics. Didn't you know?
- 16:59It's way more robust right now. This, this cancer immunology
- 17:02doesn't really work. Luckily I was too if you're
- 17:05stubborn, maybe it changed my mind, but it would really broke
- 17:10the field broke open in 2011 when first their really
- 17:16immunotherapy started having real effective Melanoma, the
- 17:20infusion and the antibodies. You know, what has become a, a,
- 17:23you know, a very, you know, changing world in, in, in cancer
- 17:28Care now. And now we have all these
- 17:30different targets. But, but I would say as an
- 17:32immunologist, we're still scratching the surface of this.
- 17:36But one of the things that really made that happen, I mean,
- 17:40they figured out some of the molecules that regulate how T
- 17:43cells get activated. That's great.
- 17:45And and then you can activate them better.
- 17:47And it's just because we learned how tumors are turning off the
- 17:50immunity because eventually cancers have to evolve immune
- 17:55evasion. They have to evolve this in
- 17:58order to continue to grow and develop.
- 18:02What they build is sort of an invisibility cloak where you
- 18:06know, they kind of they, they wrap themselves and, and become
- 18:09more invisible and they turn off the T cells, They might turn off
- 18:13the the B cell responses. We can see that immunity in
- 18:17tumor tissue. We can see in breast cancers
- 18:20when you have more immune cells that are sitting around in the
- 18:23tumor. See this if we look for it under
- 18:26the microscope when we take those tumor cells, when we see
- 18:29all that immune infiltration as we call it, or those tumor
- 18:32infiltrating lymphocytes. When we see that we know
- 18:35patients tumors are going to be much more sensitive to immune
- 18:38therapy because we can wake those up.
- 18:40You wake them up and you can then, you know, target them.
- 18:42So what they're doing is there's, it's sort of like
- 18:44they're, they're, it's that Sentinel, it's sitting right
- 18:47nearby. But they can't actually kill the
- 18:50cells because the tumor has become, has sort of turned them
- 18:54off and put them to sleep. And it does a number of
- 18:56different ways. It does this, it becomes
- 18:58invisible in some ways. And so that's the, the, the core
- 19:02of how immune therapy works. But for breast cancer now that
- 19:06works for triple negative breast cancers and it works a little
- 19:09bit maybe on some ER positive breast cancer.
- 19:13But I think what to me is evolving in that field is that
- 19:17now we, you know, maybe we can use therapeutic vaccines to
- 19:20create more T cells that'll target those changes.
- 19:24We can use maybe even prevention vaccines to prevent it if, if
- 19:29it's starting to come along that target the things that are
- 19:33different in, in early, early breast cancers and try to drive
- 19:38that immunity before the cells have a chance to become
- 19:41resistant to it. And, and so I think that's part
- 19:45of what is exciting. And the other thing that the
- 19:49field has been working on is we, while it's triple negative
- 19:52breast cancer, a lot of breast cancers aren't that sensitive to
- 19:54immune therapies and we call them cold, you know, when you
- 19:58have an active immune response. It, it causes, you know, a warm,
- 20:02hot, swollen, red Welt, right? You know, when you, when you can
- 20:06get a little local infection in your skin, Well, the same kind
- 20:09of thing is happening internally, right?
- 20:12And so when you have all that immune infiltration, we, we call
- 20:15that a hot tumor and and a cold tumor means you don't have a
- 20:20whole lot of reaction to it. And so a lot of these slower
- 20:23growing ER positive breast cancers in particular are like
- 20:27that. They're not particularly
- 20:29immunologically active. And so there's a lot of work.
- 20:32And it's not just breast cancers, this is true in colon,
- 20:35a lot of colon cancers and some, you know, pancreatic cancer, you
- 20:38know, ovarian cancers and others.
- 20:40So, so a lot of the work is can we turn those cold tumors hot?
- 20:46Can we improve the infiltration into these to help clear it up?
- 20:50Because what would be ideal is if we identified individual,
- 20:54right? Let's say women with high breast
- 20:57density, women at higher risk of getting breast cancer because of
- 21:01their genetics or their exposures or, or younger women.
- 21:06Can we actually head this off before it becomes DCIS or before
- 21:11it becomes as atypia and DCIS and other things?
- 21:14We know women with, like atypia have an increased risk of
- 21:17getting breast cancer. Other women with density have an
- 21:20increased risk of getting breast cancer.
- 21:21Can we give immune therapies to help the immune system clear it?
- 21:26And, and, and, and the truth is it's probably going to be some
- 21:29combination of target drugs and maybe an immunologic response
- 21:36that we can drive to be able to do this ultimately.
- 21:40And so that's just pulling the cover off of understanding
- 21:44because it gives, it allows y'all the researchers the
- 21:49opportunity to go down that path, I think, and, and, and to
- 21:56be able to explore that more. Because when you're talking
- 21:59about it, I'm thinking, so could you, could there be like when
- 22:04you identify these protein panels and if you see those,
- 22:09then you go, OK, well, we need to give this person vaccination
- 22:15for pumping up the immune system.
- 22:17Could, could, could. Am I just like crazy or?
- 22:20No, no, that's exactly, I mean, people are looking at this,
- 22:23people are studying this. Most of the vaccines that that
- 22:26we've been busy building have been to reduce recurrence in
- 22:30women who already have a cancer. And, and those are just, you
- 22:34know, this is just clinical studies that we're trying to, to
- 22:37create and build. And, and I ran a couple of
- 22:40breast cancer vaccine studies in Boston when I was there.
- 22:44And in that case, we were just taking the cells themselves and
- 22:47killing them and, and delivering them, activating immunity.
- 22:50But, but as we get better at understanding this, we, we can,
- 22:55you know, the hope is that we, that we can move this earlier
- 22:58and really try to do it. And I talk about adaptive
- 23:01immunity, you know a lot about T cells, but but antibodies, you
- 23:04know, the big advance in Breast Cancer Care recently has been
- 23:09these antibody drug conjugates. So things that see stuff on the
- 23:13surface of cells, stick to it and then maybe can deliver a
- 23:17little microscopic amount of of payload be really chemotherapy
- 23:21payload that goes just straight to to the cell.
- 23:25Consider it like a smart bomb, right?
- 23:27And, and there's just been just so many more of these that we
- 23:32have available now for treating patients more with advanced
- 23:37disease. But now we're working on it and
- 23:39pre before surgeries and things like this.
- 23:41And they, they work. They're, they're amazing.
- 23:44But we need more targets and we need more ways to be able to do
- 23:47this. And that is this is something
- 23:50that we're working on that that this is the sort of the, the
- 23:53future version of, of, of what we've been doing that I'm I'm
- 23:57excited about. So, so we measure, when we
- 24:01measure proteins, you know, we measure antibodies.
- 24:04Those are great assays. They're very sort of well
- 24:07established. We can what we did with with
- 24:11help from your organization initially.
- 24:14And, and, and I will tell you that that pilot funding was
- 24:16really was really critical to us being able to, to develop some
- 24:21of these tests in a more rigorous way.
- 24:24It led to directly led to some NCI funding, National Cancer
- 24:28Institute funding to be able to work and develop that more.
- 24:31And, and I cannot emphasize enough how much small pilot
- 24:35grants are, you know, really help can, can help spearhead,
- 24:39you know, really tell us, OK, is this really something worth
- 24:42pursuing? Do we need to think in a
- 24:43different direction? And, and that's what it did with
- 24:47us. We, we were looking at DCIS.
- 24:50What we really found was we found more antibody responses
- 24:53and in patients with later with stage 2, stage 3 cancers, we
- 24:57weren't, we did see it in some stage ones.
- 24:59We didn't see a lot in DCIS and sort of told us that immunity
- 25:04that we could measure maybe, maybe not so much.
- 25:07That. As early as that, not to say it
- 25:10wasn't there, but that we weren't picking it up.
- 25:13The, the technologies that we use that was that, that are
- 25:16unique is that we can make a lot of different proteins, 10s of
- 25:20thousands of different proteins in small amounts.
- 25:22So we make these protein arrays and then we can measure
- 25:25antibodies across those arrays. And so we can remember you've
- 25:29got maybe 100,000 different variations of proteins in your
- 25:34body. And so you have to be able to
- 25:36look at a lot of different versions of this to be able to
- 25:39see it. And, and so we could start to
- 25:42scan across the whole proteome of, you know, what are those
- 25:46antibodies to? And, and those were the projects
- 25:49that we worked on. We do this in breast cancer.
- 25:52We also did this in ovarian cancer and in lung cancer and,
- 25:55and create, you know, a couple different cancer types.
- 25:58And, and I think that they, some of those tests may end up being
- 26:02useful to distinguish risk and distinguish things, but probably
- 26:06more maybe in stage 2 and 3 cancers, perhaps more than than
- 26:11stage 0 or stage 1. I, I think those are hard in
- 26:14breast cancers. But the next to me, the exciting
- 26:18thing that my laboratory has been working on recently has
- 26:22been instead of looking at this at the protein level, looking at
- 26:26the adaptive immunity at the protein level, we're going into
- 26:28the sequences. And the reason why we're going
- 26:32into the sequences is now we have the ability, we've been
- 26:35working on assays and tools to be able to measure that adaptive
- 26:39immunity really easily, really sensitively, really cheaply.
- 26:43So we can start to look at populations of what's happening
- 26:47with your TS and B cell sequences in your blood, what's
- 26:51happening now, what's happening next week, next month, next
- 26:54year. And to be able to do that from
- 26:57the peripheral blood, I think we'll end up taking these assays
- 27:01to a whole nother really ultra deep sequencing because we can
- 27:05sequence millions of sequences at once.
- 27:08And and that has relied on a couple of advances in sequencing
- 27:14systems. One of them is being able to do
- 27:17longer read sequencing, being able to do it at the bench top.
- 27:19Wow. Yeah, we we literally the
- 27:23sequencer we use is the size of your USB stick.
- 27:27Wow, it's. Crazy, right?
- 27:30It's so portable. This stuff can be done anywhere
- 27:36and, and we can run these sequences through and we can get
- 27:39the sequences of these B&T cell receptors and in, in throughput
- 27:44and we can start to, you can barcode these things and, and
- 27:47start to look at these in population.
- 27:50And I think if we do this, we'll be able, you know, you have to
- 27:54look at thousands of people to understand, you know, is your
- 27:58adaptive immunity changing differently, you know, from one
- 28:02person, one person to another And you over time.
- 28:06What we've found, at least when we start to do this is I can
- 28:10actually they're fingerprints essentially.
- 28:12I can tell your T cell receptors are different than my T cell
- 28:16receptors. And if I run your assays
- 28:19multiple times, I see your T cell receptors and your B cell
- 28:23receptors are different than mine.
- 28:24And, and, and, and that looks like yours.
- 28:27And these look like mine. And it's because your immune
- 28:29system has seen all this history.
- 28:31You know, it might be the flu that you caught when you were
- 28:3325, and it might be the shingles that you got when you were 55.
- 28:38And it might be the breast cancer that you got when you
- 28:40were 45, right? That, that dictate how those
- 28:44sequences change and evolve over time and, and you're carrying
- 28:47that history, that immunologic history with you of all the
- 28:52things that you've been exposed to.
- 28:53And so, and then when you get a vaccine or when you get an
- 28:59infection or you get a cancer, that could change.
- 29:03And what we're starting to look at is do we, can we see those
- 29:06changes? And, and if we can see that, I
- 29:10believe I don't know yet that that might be much, much more
- 29:13sensitive and more comprehensive way of looking at adaptive
- 29:17immunity compared to what we've been doing, which, which is
- 29:21looking at hundreds, thousands of different protein changes.
- 29:24Now we can get to the root of the sequences and say, how does
- 29:28this really change? And, and, and what we've learned
- 29:31technically as a sequencing is a lot more sensitive in some ways
- 29:35than getting to protein. So, so that's the, that to me is
- 29:39the future part of, of where we're going with this, where we
- 29:42can fish these sequences out of tumors too and, and start to say
- 29:46what, what are people naturally seeing in cancers?
- 29:49And, and I, I, I think this will lead to in, in the diagnostic
- 29:53space and potential in the therapeutic space.
- 29:55I. Think that that is so promising
- 29:58to think about that this is we've come so far and yet
- 30:03there's still an opportunity to go even further and I just
- 30:07that's the whole thing. It's like, well, who said we had
- 30:11to stop it imaging, you know, or a. 100%, yeah.
- 30:16It's just like so, so if that's not exactly the right thing, why
- 30:21did we think that that was the right thing to just stop there?
- 30:25Let let's let's just get on the move.
- 30:27And you are so energizing for me because I love this.
- 30:32I love listening to all of this research.
- 30:35And the promise of new approaches is so expansive,
- 30:40which I think is also important for our audience to realize is
- 30:44that, yeah, we we're coming along really well, but we got
- 30:48some other things we can do even better, which I think is just so
- 30:52exciting. So I really appreciate you're
- 30:56spending your time and energy and brain power and I just
- 31:01cheered you on and I'd like for you to probably finish this
- 31:04maybe by the end of the week, you know, you can just take it
- 31:07on till the end of this week and then you can move on to
- 31:09something else. Move on to something else.
- 31:12Yeah, well, you know, if nothing persistent, my Mama might have
- 31:18had a different word for it, but you know.
- 31:21Well, I have AI have a card that's my favorite card and I
- 31:24have it on my refrigerator and it says persistence is not a
- 31:28pretty thing. So I that's probably the I'm I'm
- 31:32right in that ballpark. We can hold hands and smile and
- 31:35laugh. So that'll. 100%, yeah.
- 31:37Thank you so much, Doctor Anderson.
- 31:40It has been a joy and so informative and I hope that we
- 31:44can let lots of people hear things.
- 31:46And one other person I wanted you to maybe listen to is Doctor
- 31:51Francis Carr and she, I'm not sure if you're familiar with
- 31:55her, but we interviewed her and she's looking at indicators with
- 32:01thyroid. So I thought that was a very
- 32:04unique approach too. So, so it's nice, interesting
- 32:08folks. So thank you so much and I hope
- 32:10you have very good success and keep us posted on that wonderful
- 32:14success you're going to have. Thank you so much.
- 32:17And I just really want to give just, you know, a shout out to
- 32:22everybody who's who's been, you know, both working in this field
- 32:26of trying to figure out, you know, what's happening early so
- 32:28we can head it off at the pass and we can find it early.
- 32:31But, but really just a shout out to you and, and, and all your
- 32:35efforts and your organization's efforts over the years to help
- 32:39support this so that we can get better at it.
- 32:43Well, thank you so much. It's my joy.
- 32:45Thank you so much. OK.
- 32:46Great to meet you. Bye, bye, bye.
- 32:49This episode of Isn't That Interesting was made possible
- 32:52thanks to volunteers and donors just like you.
- 32:54It was hosted by Martha Kaley, founderofearlier.org and edited
- 32:59by Liam Mcburney. I'm Valerie Amsterdam, reminding
- 33:03you that for the last 30 years, this is North Carolina based
- 33:06organization has helped fund groundbreaking research all over
- 33:10the world from molecular imaging to a sensitive blood test for
- 33:14breast cancer. Plain and simple, earlier
- 33:16detection saves lives. And you can help host a
- 33:19fundraising event, make a donation for volunteer your
- 33:22time. You can find us not only on the
- 33:25web, but on Facebook and Instagram too.
- 33:27Let's change the picture of breast cancer together.